LobbyingAccendra Health lobbying by quarter
Accendra Health ACH's latest lobbying report covers Q3 2026, at $200K. The four quarters Q4 2025–Q3 2026 total $1.2M. Its first report covers Q4 2022; the issues it reports most are Medicare/Medicaid and Health Issues.
- Latest quarter
- $200K
- Q3 2026 · 1 reports
- Last 12 months
- $1.2M
- Last 4 quarters
- vs last quarter
- −39.4%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $410K | 2 |
| Q1 2023 | $280K | 2 |
| Q2 2023 | $280K | 2 |
| Q3 2023 | $290K | 2 |
| Q4 2023 | $400K | 2 |
| Q1 2024 | $310K | 2 |
| Q2 2024 | $260K | 2 |
| Q3 2024 | $260K | 2 |
| Q4 2024 | $290K | 2 |
| Q1 2025 | $280K | 2 |
| Q2 2025 | $280K | 2 |
| Q3 2025 | $270K | 2 |
| Q4 2025 | $320K | 2 |
| Q1 2026 | $360K | 2 |
| Q2 2026 | $330K | 2 |
| Q3 2026 | $200K | 1 |
Policy issues the reports name
- Medicare and Medicaid31 reports
- Health issues29 reports
- Budget and appropriations9 reports
- Trade6 reports
- Veterans6 reports
- Defense6 reports
- Environment and Superfund4 reports
- Government issues3 reports
- Manufacturing2 reports
- Transportation1 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES31 reports
- SENATE31 reports
- Health & Human Services, Dept of (HHS)3 reports
- Centers For Medicare and Medicaid Services (CMS)2 reports
- Office of Management & Budget (OMB)1 reports
- Office of the Vice President of the United States1 reports
- U.S. Trade Representative (USTR)1 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAccendra Health | $3.6M | 16 quarters |
| NVG | $1.2M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 09/28for Q3 | In-house | $200K |
| 07/20for Q2 | NVG | $80K |
| 07/13for Q2 | In-house | $250K |
| 07/13for Q2 | In-house | $250K |
| 04/20for Q1 | NVG | $80K |
| 04/15for Q1 | In-house | $280K |
| 01/20for Q4 2025 | NVG | $80K |
| 01/19for Q4 2025 | In-house | $240K |
| 25/10/20for Q3 2025 | NVG | $80K |
| 25/10/15for Q3 2025 | In-house | $190K |
| 25/07/20for Q2 2025 | NVG | $80K |
| 25/07/16for Q2 2025 | In-house | $200K |
| 25/04/19for Q1 2025 | NVG | $80K |
| 25/04/16for Q1 2025 | In-house | $200K |
| 25/01/20for Q4 2024 | NVG | $80K |
| 25/01/20for Q4 2024 | In-house | $210K |
| 24/10/21for Q3 2024 | NVG | $80K |
| 24/10/15for Q3 2024 | In-house | $180K |
| 24/07/22for Q2 2024 | NVG | $80K |
| 24/07/22for Q2 2024 | In-house | $180K |